Roger Tung - Concert Pharmaceuticals Co-Founder, CEO and President and Director
| CNCEDelisted Stock | USD 8.37 0.01 0.12% |
CEO
Dr. Roger Tung is the CoFounder, President, Director and CEO of Concert Pharmaceuticals Inc. He is also a member of the board of directors of Flex Pharma, Inc., a public pharmaceutical company. Before founding Concert, Dr. Tung was a founding scientist at Vertex Pharmaceuticals Incorporated, a pharmaceutical company, where he was employed from 1989 to 2005, most recently as its Vice President of Drug Discovery. Prior to Vertex, he held various positions at Merck, Sharp Dohme Research Laboratories, a global healthcare provider, and The Squibb Institute for Medicinal Chemistry since 2006.
| Age | 63 |
| Tenure | 18 years |
| Professional Marks | Ph.D |
| Phone | 781 860 0045 |
| Web | https://www.concertpharma.com |
Roger Tung Latest Insider Activity
Tracking and analyzing the buying and selling activities of Roger Tung against Concert Pharmaceuticals stock is an integral part of due diligence when investing in Concert Pharmaceuticals. Roger Tung insider activity provides valuable insight into whether Concert Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Concert Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Concert Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Roger Tung over a year ago Disposition pursuant to a tender of shares in a change of control transaction by Roger Tung of Concert Pharmaceuticals |
Concert Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.3853) % which means that it has lost $0.3853 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0868) %, meaning that it created substantial loss on money invested by shareholders. Concert Pharmaceuticals' management efficiency ratios could be used to measure how well Concert Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Concert Pharmaceuticals currently holds 14.51 M in liabilities with Debt to Equity (D/E) ratio of 0.11, which may suggest the company is not taking enough advantage from borrowing. Concert Pharmaceuticals has a current ratio of 9.83, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Concert Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Found 3 records | CEO Age | ||
| Nhon Luc | Sun Life Financial | N/A | |
| Dean Connor | Sun Life Financial | 63 | |
| Michael Kehoe | Kinsale Capital Group | 58 | |
Management Performance
| Return On Equity | -1.09 | |||
| Return On Asset | -0.39 |
Concert Pharmaceuticals Leadership Team
Elected by the shareholders, the Concert Pharmaceuticals' board of directors comprises two types of representatives: Concert Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Concert. The board's role is to monitor Concert Pharmaceuticals' management team and ensure that shareholders' interests are well served. Concert Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Concert Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Nancy Stuart, Chief Officer | ||
| James Cassella, Senior Vice President chief development officer | ||
| Marc Becker, Chief Officer | ||
| Christine Boisclair, Vice President - Regulatory Affairs | ||
| Justine Koenigsberg, VP of Corporate Communications and Investor Relations | ||
| Jeffrey Munsie, Chief Sec | ||
| Nabil PharmD, VP Devel | ||
| Roger Tung, Co-Founder, CEO and President and Director | ||
| Mba MBA, CoFounder Chairman |
Concert Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Concert Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.09 | |||
| Return On Asset | -0.39 | |||
| Operating Margin | (2.88) % | |||
| Current Valuation | 86.63 M | |||
| Shares Outstanding | 48.02 M | |||
| Shares Owned By Insiders | 3.77 % | |||
| Shares Owned By Institutions | 77.05 % | |||
| Number Of Shares Shorted | 1.08 M | |||
| Price To Earning | 3.08 X | |||
| Price To Book | 1.67 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Other Consideration for investing in Concert Stock
If you are still planning to invest in Concert Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Concert Pharmaceuticals' history and understand the potential risks before investing.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |